Insulin

Insulin has been studied in 634 papers since 1980: 63 trials and 232 observational studies in people, 70 in animals, 12 in cells, 223 reviews; 256 in the past year. The newest story, Nov 15, 2026: “Exercise and insulin boosted galactose uptake in older men”.

Intervention

634 papers study it358 findingsUpdated

MeSH

Research on it is growing 17% faster than aging research as a whole: 440 papers in the latest year counted

58 new papers in 30 daysSee all 627 papers on insulin

At a glance

Independent labs report increased senescence with insulin in human cells but decreased senescence in mice; other studies report decreased senescence in human cells or no clear effect in mice. Human trials report less postoperative delirium with intranasal insulin, while a trial reports impaired verbal episodic memory during insulin stimulation. Some papers declare ties to insulin developers.

358 findings in 234 papers from 1991 to 2026, 39 of them since April 2026

Independent labs found the same change in cells, mice and people. 158 independent labs in 45 countries; 200 trials, 8 about aging, 80 with no results posted.

“insulin use (HR 1.34, 95% CI, 1.08-1.66) were significant diabetes-related predictors of all clinical fractures.”
Predictors of Fracture in Middle-Aged and Older Adults With Type 2 Diabetes and Overweight or ObesityThe Journal of clinical endocrinology and metabolism2024doi:10.1210/clinem/dgae623

24 of its findings point the other way.

Cells, mice and humans: replicated by independent labs. Worms or flies: a single group.
  • 158 independent labs in 45 countries
  • 24 findings against
  • 200 trials, 8 about aging, 80 with no results posted
  • Funders: National Institutes of Health and others
  • 25 of 314 findings with company ties
  • 50 of 200 trials sponsored by its developers
  • Human trial63
  • Humans229
  • Animals66
  • Model organisms4
  • Cells12
  • In silico2

22 studies gave insulin to people and measured what changed.

What changedDesignPeopleSource

up: Increases skeletal muscle galactose uptake

Randomized trialtwo 4 h study days8 peopleMen68 ± 4 yearsOlder adults; hyperinsulinemic–euglycemic clamp in healthy menThe Journal of physiology, Nov 15, 2026

no change: Has no effect on postoperative deliriumincidence 11.1% versus 19% with saline; association not significant

Randomized trialperioperative78 peopleolderOlder adults; surgical patients without type 2 diabetes mellitusAging clinical and experimental research, Aug 1, 2026

down: Lowers the risk of postoperative delirium16.7% vs. 46.7%, P = 0.012

down: Decreases IL-1βP < 0.05

Randomized trialsingle dose one day preoperatively60 peopleOlder adults; postoperative days 1, 2, and 3 after radical esophagectomyResearch Square, Feb 9, 2026

down: Lowers the risk of postoperative delirium10.9% vs. 30.4%

Randomized trial5 days96 peopleage ≥ 60 yearsElderly individuals scheduled for hip fracture surgeryBMC anesthesiology, Oct 27, 2025

up: Increases mPACC5

down: Decreases glial fibrillary acidic protein

Randomized trial4 weeksPatient cohortsAlzheimer's & dementia : the journal of the Alzheimer's Association, Oct 1, 2025

What did studies of insulin find?

163

Studies of insulin measured 163 outcomes; the most studied are cognitive function (12 studies), cellular senescence (8) and body weight (7).

Cognitive function

upin humans8upin reviews2no changein humans1upin mice1

12 studies
  1. Insulin improves cognitive function in humans (scheduled for elective orthopaedic surgery or pancreatic surgery with general anaesthesia) (P < 0.001, P = 0.001).

    “Insulin treatment significantly increased postoperative MMSE and MoCA-B scores in group I than in group S”

    Human trialscheduled for elective orthopaedic surgery or pancreatic surgery with general anaesthesiaintranasal administration40 IU/400 μLfrom 5 minutes before anaesthesia induction until 3 days postoperativelyn = 140

    Effect of intranasal insulin on perioperative cognitive function in older adults: a randomized, placebo-controlled, double-blind clinical trial

    Age and ageing

  2. Insulin improves cognitive function in humans (metabolic syndrome undergoing noncardiac surgery) (P < 0.05).

    “The insulin group indicated better cognitive functional performance on language and memory test than the placebo group (P < 0.05).”

    Human trialmetabolic syndrome undergoing noncardiac surgery40 IU7 days

    Protective effect of intranasal insulin on postoperative cognitive dysfunction in elderly patients with metabolic syndrome undergoing noncardiac surgery: a randomized clinical trial

    Aging clinical and experimental research

  3. Insulin showed no clear effect on cognitive function in humans (frail older adults with type 2 diabetes and HFpEF) (Montreal Cognitive Assessment 19.00 to 19.1 (P = 0.81)).

    “19.00 ± 3.71 vs. 19.1 ± 3.56 (P = 0.81) in the insulin group”

    Human trialfrail older adults with type 2 diabetes and HFpEF1 month

    Empagliflozin Improves Cognitive Impairment in Frail Older Adults With Type 2 Diabetes and Heart Failure With Preserved Ejection Fraction

    Diabetes care

  4. Insulin is linked with better cognitive function in humans (type 1 diabetes) (β = +2.92, p = 0.012).

    “Higher insulin dose (β = +2.92 and p = 0.012) was independently associated with better cognitive performance.”

    Humanstype 1 diabetes

    Clinical and Metabolic Predictors of Cognitive Impairment in Type 1 Diabetes: The Role of Peripheral Neuropathy and Hypoglycaemia Unawareness. Findings From a HAD-1 Study

    Diabetes/metabolism research and reviews

  5. Insulin improves cognitive function in humans (type 2 diabetes mellitus).

    “in patients with T2DM, improvements in memory and perfusion in the insular cortex are observed”

    Reviewtype 2 diabetes mellitus

    Intranasal insulin in the correction of cognitive impairments with central insulin resistance. A review

    Consilium Medicum

  6. Insulin improves cognitive function (via olfactory and trigeminal pathways).

    “intranasal insulin administration emerges as a promising non-invasive therapeutic approach that bypasses the blood-brain barrier via olfactory and trigeminal pathways, suggesting significant potential for cognitive enhancement”

    Reviewvia olfactory and trigeminal pathwaysintranasal

    Insulin in brain: The physiological functions and therapeutic insights for neurodegenerative diseases

    Life sciences

  7. Insulin improves cognitive function in an anorexia nervosa-like dietary restriction mouse model.

    “Insulin-polymer treatment restored cognitive function and decreased hyperactivity in the AN-like model.”

    Animalsin an anorexia nervosa-like dietary restriction mouse modelPSA-RA-based polymer insulin delivery system1% w/w insulin

    Sustained insulin treatment restoring metabolic status, body weight, and cognition in an anorexia nervosa-like animal model in mice

    Behavioural brain research

  8. Insulin improves cognitive function in patients with mild cognitive impairment and Alzheimer's disease.

    “the administration of certain antidiabetic drugs, such as intranasal insulin, metformin, incretins and thiazolidinediones, can improve cognitive function and memory”

    Reviewin patients with mild cognitive impairment and Alzheimer's diseaseintranasal

    The role of antidiabetic drugs in the treatment of Alzheimer's disease: systematic review

    Problemy endokrinologii

  9. Insulin improves cognitive function in preclinical and clinical studies of AD.

    “improved cognitive and functional outcomes”

    Reviewin preclinical and clinical studies of AD

    Targeting immunometabolic pathways for combination therapy in Alzheimer's disease

    Alzheimer's & dementia (New York, N. Y.)

  10. Insulin improves cognitive function in humans (measured by MMSE versus placebo) (SMD 1.11, 95% CI (0.87, 1.35)).

    “Of these treatments, intranasal insulin 20 IU (ITSN20), glucagon-like peptide-1 (GLP-1), and dipeptidyl peptidase 4 inhibitor (DPP-4) were associated with significantly improved MMSE scores”

    Reviewmeasured by MMSE versus placebointranasal20 IUn = 333

    Efficacy and safety of hypoglycemic drugs in improving cognitive function in patients with Alzheimer's disease and mild cognitive impairment: A systematic review and network meta-analysis

    Frontiers in neurology

All 12

Cellular senescence

upin human cells3no changein mice2downin human cells1upin humans1+2

8 studies
  1. Insulin showed no clear effect on cellular senescence in bone marrow-derived macrophages and gingival tissues.

    “Insulin glycemic control was unable to reverse these pathological changes in bone marrow-derived macrophages and gingival tissues”

    Animalsin bone marrow-derived macrophages and gingival tissues

    DHFR-Driven Metabolic Memory Sustains Periodontal Tissue Destruction

    Journal of dental research

  2. Insulin induces cellular senescence in CD4+ cell cultures.

    “Exposure of CD4+ cells to insulin induced a senescent state recognized by cell cycle arrest and DNA content enrichment measured by flow cytometry.”

    Cellsin CD4+ cell cultures

    Insulin Sensitivity Controls Activity of Pathogenic CD4+ T Cells in Rheumatoid Arthritis

    Cells

  3. Insulin showed no clear effect on cellular senescence in mice (normalization of plasma glucose in dietary obesity mouse model).

    “normalization of plasma glucose by insulin treatment had no effect on senescent cells”

    Animalsnormalization of plasma glucose in dietary obesity mouse model

    SGLT2 inhibition eliminates senescent cells and alleviates pathological aging

    Nature aging

  4. Insulin induces cellular senescence in humans.

    “hyperinsulinemia and associated insulin resistance (IR) promote CS in both human adipose and liver cells”

    Review

    Increased cell senescence in human metabolic disorders

    The Journal of clinical investigation

  5. Insulin increases cellular senescence in LIRKO mice with persistent hyperinsulinemia.

    “In contrast, the persistent hyperinsulinemia in LIRKO mice enhanced senescence in white adipose tissue.”

    Animalsin LIRKO mice with persistent hyperinsulinemiawhite adipose tissue

    Chronic hyperinsulinemia promotes human hepatocyte senescence

    Molecular metabolism

  6. Insulin induces cellular senescence in human hepatocytes in vitro.

    “exposing the hepatocytes to prolonged hyperinsulinemia promotes the onset of senescence by increasing the expression of p53 and p21”

    Cellsin human hepatocytes in vitrohepatocyte

    Chronic hyperinsulinemia promotes human hepatocyte senescence

    Molecular metabolism

  7. Insulin increases cellular senescence in H-BMSCs under hyperinsulinemic conditions.

    “H-BMSCs incubated in hyperglycemic and hyperinsulinemic conditions similarly showed these phenotypes of DM-BMSCs.”

    Cellsin H-BMSCs under hyperinsulinemic conditions

    Insulin impedes osteogenesis of BMSCs by inhibiting autophagy and promoting premature senescence via the TGF-β1 pathway

    Aging

  8. Insulin decreases cellular senescence in human cells under physiological or 1% cigarette smoke extract exposure.

    “Results showed that insulin receded cellular senescence in different time and concentration”

    Cellsunder physiological or 1% cigarette smoke extract exposure

    Insulin in high concentration recede cigarette smoke extract induced cellular senescence of airway epithelial cell through autophagy pathway

    Biochemical and biophysical research communications

  9. Insulin decreases cellular senescence in mice (STZ-induced diabetic mice).

    “Administration of insulin at doses that maintained normoglycemia or mild hypoglycemia suppressed the changes induced by STZ.”

    AnimalsSTZ-induced diabetic micekidneydoses that maintained normoglycemia or mild hypoglycemia

    Hyperglycemia causes cellular senescence via a SGLT2- and p21-dependent pathway in proximal tubules in the early stage of diabetic nephropathy

    Journal of diabetes and its complications

More on Cellular senescence

Body weight

upin humans5no changein humans1upin mice1

7 studies
  1. Insulin showed no clear effect on body weight in humans.

    “INI treatment did not change HbA1c, weight, waist circumference or BMI (Fig. C, D), but fasting serum glucose decreased in DM-Placebo group (p = 0.03) (Supplementary Table A.2.).”

    Human trial24 weeks with 24 weeks of follow-upn = 244

    MemAID: Memory advancement with intranasal insulin vs. placebo in type 2 diabetes and control participants: a randomized clinical trial

    Journal of neurology

  2. Insulin increases body weight in humans (compared with metformin or acarbose plus sulfonylurea).

    “BW increased in group A and decreased in the other groups.”

    Human trialcompared with metformin or acarbose plus sulfonylureainsulin-Zn0.3 IU/kg body weightfour monthsn = 12

    Comparison between acarbose, metformin, and insulin treatment in type 2 diabetic patients with secondary failure to sulfonylurea treatment

    Diabete & metabolisme

  3. Insulin increases body weight in non-diabetic populations.

    “identified elevated insulin secretion as a key contributor to weight gain”

    Reviewin non-diabetic populations

    Why hyperinsulinemia is detrimental to weight loss: insights from type 1 diabetes

    BMC medicine

  4. Insulin increases body weight in an anorexia nervosa-like dietary restriction mouse model.

    “Diet restriction mice treated with the insulin delivery system showed body weight restoration.”

    Animalsin an anorexia nervosa-like dietary restriction mouse modelPSA-RA-based polymer insulin delivery system1% w/w insulin

    Sustained insulin treatment restoring metabolic status, body weight, and cognition in an anorexia nervosa-like animal model in mice

    Behavioural brain research

  5. Insulin increases body weight in humans (anorexic malnourished frailty).

    “In the anorexic malnourished frail individual, early use of insulin, due to its weight gain and anabolic properties, is appropriate.”

    Reviewanorexic malnourished frailty

    Cardiovascular risk reduction in older people with type 2 diabetes mellitus-a comprehensive narrative review

    Diabetes research and clinical practice

  6. Insulin increases body weight in humans.

    “Insulin, sulfonylureas, thiazolidinediones and meglitinides may increase body weight.”

    Review

    Weight-centric treatment of type 2 diabetes mellitus

    Obesity pillars

  7. Insulin increases body weight in humans (type 2 diabetes).

    “Insulin clearly causes weight gain, recurrent hypoglycemia, and, other potential adverse effects, including iatrogenic hyperinsulinemia.”

    Reviewtype 2 diabetes

    Insulin Therapy Increases Cardiovascular Risk in Type 2 Diabetes

    Progress in cardiovascular diseases

Lifespan

downin A. arabiensis1upin humans1downin mice1upin worms1

4 studies
  1. Insulin extends lifespan in worms (lin-35 mutant compared with N2 wild-type worms).

    “IGF-1 or insulin increased the lifespan of lin-35 worms compared to N2 worms”

    Model organismslin-35 mutant compared with N2 wild-type worms

    Insulin and IGF-1 extend the lifespan of Caenorhabditis elegans by inhibiting insulin/insulin-like signaling and mTOR signaling pathways: C. elegans - Focused cancer research

    Biochemical and biophysical research communications

  2. Insulin extends lifespan in diabetes.

    “improved glycemia and increased patient life span”

    Reviewin diabetes

    The Evolution of Diabetes Treatment Through the Ages: From Starvation Diets to Insulin, Incretins, SGLT2-Inhibitors and Beyond

    Journal of the Indian Institute of Science

  3. Insulin shortens lifespan in the insecticide susceptible strain (SENN).

    “Insulin ingestion significantly reduced longevity in the insecticide susceptible strain.”

    Model organismsin the insecticide susceptible strain (SENN)

    The effects of ingestion of hormonal host factors on the longevity and insecticide resistance phenotype of the major malaria vector Anopheles arabiensis (Diptera: Culicidae)

    PloS one

  4. Insulin shortens lifespan in mice (Mecp2(NULL/Y) mice).

    “we treated Mecp2(NULL/Y) mice with insulin, which also decreased lifespan.”

    AnimalsMecp2(NULL/Y) micemales

    Insulinotropic treatments exacerbate metabolic syndrome in mice lacking MeCP2 function

    Human molecular genetics

IL-6

downin humans3

3 studies
  1. Insulin decreases IL-6 in humans (scheduled for elective orthopaedic surgery or pancreatic surgery with general anaesthesia) (P = 0.034, P = 0.044).

    “inhibited postoperative IL-6 and S100-β levels in Group I compared to Group S (P = 0.034, P = 0.044, respectively)”

    Human trialscheduled for elective orthopaedic surgery or pancreatic surgery with general anaesthesiaintranasal administrationserum40 IU/400 μLfrom 5 minutes before anaesthesia induction until 3 days postoperativelyn = 140

    Effect of intranasal insulin on perioperative cognitive function in older adults: a randomized, placebo-controlled, double-blind clinical trial

    Age and ageing

  2. Insulin decreases IL-6 in humans.

    “Besides, the serum levels of IL-6, TNF-α and S100β at T2−5 in the insulin group were significantly lower than those of the control group (IL-6: mean difference at T2, −4.14, p = 0.036; T3, −3.84, p = 0.039; T4, −3.37, p = 0.013; T5, −2.57, p = 0.042”

    Human trialintranasalserumstarting 2 days before surgery until 1 h before admission to the operating roomn = 61

    Efficacy and safety of intranasal insulin on postoperative cognitive dysfunction in elderly patients after laparoscopic radical resection of colorectal cancer: a double-blind pilot study

    Frontiers in aging neuroscience

  3. Insulin decreases IL-6 in humans after laparoscopic radical resection of colorectal cancer (mean difference at T2, -4.14).

    “The serum levels of IL-6, TNF-α and S100β at T2−5 in the insulin group were significantly lower than those of the control group”

    Human trialafter laparoscopic radical resection of colorectal cancerserumn = 61

    Efficacy and safety of intranasal insulin on postoperative cognitive dysfunction in elderly patients after laparoscopic radical resection of colorectal cancer: a double-blind pilot study

    Frontiers in aging neuroscience

  4. Insulin decreases IL-6 in humans (preoperative surgical patients) (MD -2.52; 95% CI -3.45 to -1.58).

    “Significant reductions in IL-6 (MD -2.52; 95% CI -3.45 to -1.58) and TNF-α (MD -5.02; 95% CI -8.67 to -1.36) were observed.”

    Reviewpreoperative surgical patients

    Effect of preoperative intranasal insulin on postoperative delirium in adult surgical patients: a systematic review, meta-analysis, and trial sequential analysis

    Perioperative medicine (London, England)

More on IL-6

Inflammation

downin humans3

3 studies
  1. Insulin decreases inflammation in humans.

    “Notably, patients in Group I exhibited lower CRP and IL-6 serum concentrations at T1 (P < 0.001; Table ).”

    Human trialintranasal5 daysn = 96

    Effect of perioperative intranasal insulin on postoperative delirium in elderly hip fracture patients undergoing general anesthesia: a randomized controlled study

    BMC anesthesiology

  2. Insulin decreases inflammation in humans (undergoing hip fracture surgery under general anesthesia) (P < 0.001).

    “Serum IL-6 and CRP levels at T1 were lower in the insulin group compared to controls (P < 0.001)”

    Human trialundergoing hip fracture surgery under general anesthesiaserum20 units in 0.5 mL twice dailybeginning two days preoperatively and continuing for five daysn = 92

    Effect of perioperative intranasal insulin on postoperative delirium in elderly hip fracture patients undergoing general anesthesia: a randomized controlled study

    BMC anesthesiology

  3. Insulin decreases inflammation in humans (metabolic syndrome undergoing noncardiac surgery) (P < 0.05 and P < 0.001).

    “Mean peripheral plasma concentration of TNF-α (P < 0.05) and CRP (P < 0.001) in the insulin group was significantly declined compared with the placebo group on D3 and D7.”

    Human trialmetabolic syndrome undergoing noncardiac surgeryplasma40 IU7 days

    Protective effect of intranasal insulin on postoperative cognitive dysfunction in elderly patients with metabolic syndrome undergoing noncardiac surgery: a randomized clinical trial

    Aging clinical and experimental research

  4. Insulin decreases inflammation in humans among adults undergoing surgery (MD: -3.10, 95% CI: -4.42, -1.78).

    “Its administration was also associated with a statistical decrease in the serum concentration of TNF-α (MD: -3.10, 95% CI: -4.42, -1.78)”

    Reviewamong adults undergoing surgery

    Use of intranasal insulin on postoperative delirium: A systematic review and meta-analysis of randomised controlled trials

    Indian journal of anaesthesia

More on Inflammation

HOMA-IR

downin humans2no changein humans1

3 studies
  1. Insulin decreases HOMA-IR in humans (undergoing joint replacement) (P=0.002).

    “HOMA-IR was significantly lower on D 3 in insulin group than placebo group (P=0.002).”

    Human trialundergoing joint replacementtwice 40 IU3 daysn = 212

    Effect of intranasal insulin on osteocalcin levels and postoperative delirium in elderly patients undergoing joint replacement

    medRxivPreprint

  2. Insulin decreases HOMA-IR in T2DM participants.

    “DM-INI group had lower plasma insulin (p = 0.006) and HOMA-IR (Homeostatic Model Assessment of Insulin Resistance; p = 0.013) (Fig. A, B).”

    Human trialin T2DM participants24 weeks with 24 weeks of follow-up

    MemAID: Memory advancement with intranasal insulin vs. placebo in type 2 diabetes and control participants: a randomized clinical trial

    Journal of neurology

  3. Insulin showed no clear effect on HOMA-IR in humans (preoperative surgical patients).

    “No significant differences were found in serum or CSF glucose, or HOMA-IR.”

    Reviewpreoperative surgical patients

    Effect of preoperative intranasal insulin on postoperative delirium in adult surgical patients: a systematic review, meta-analysis, and trial sequential analysis

    Perioperative medicine (London, England)

More on HOMA-IR

HbA1c

downin humans2

2 studies
  1. Insulin decreases HbA1c in humans (compared with acarbose plus sulfonylurea in secondary sulfonylurea failure).

    “both insulin and metformin plus SFS provided better glycaemic control than acarbose plus SFS”

    Human trialcompared with acarbose plus sulfonylurea in secondary sulfonylurea failureinsulin-Zn0.3 IU/kg body weightfour monthsn = 12

    Comparison between acarbose, metformin, and insulin treatment in type 2 diabetic patients with secondary failure to sulfonylurea treatment

    Diabete & metabolisme

  2. Insulin is linked with lower HbA1c in humans.

    “During follow-up, HbA1c and body weight diverged significantly, with higher levels observed in the COAD group.”

    HumansNewly diagnosed type 2 diabetes after successful initial intensive treatment and treatment cessation; compared with combined oral antidiabetic drugs

    Long-term effectiveness on glycemic control of insulin compared to combined oral antidiabetic drugs for initial intensive treatment in newly diagnosed type 2 diabetes: A duplicated target trial

    Medicine

More on HbA1c

IFNG

downin human cells2

2 studies
  1. Insulin inhibits IFNG in CD4+ cell cultures and in patients with hyperinsulinemia.

    “Insulin suppressed IFNγ production and induced the senescence-associated secretome in CD4+ cell cultures and in patients with hyperinsulinemia.”

    Cellsin CD4+ cell cultures and in patients with hyperinsulinemia

    Insulin Sensitivity Controls Activity of Pathogenic CD4+ T Cells in Rheumatoid Arthritis

    Cells

  2. Insulin decreases IFNG in human cells.

    “It also reduced IFNγ production.”

    CellsCD4 T cells

    Hyperinsulinemia counteracts inflammation by suppressing IFNγ and inducing senescence in CD4 + T cells of patients with rheumatoid arthritis

    medRxivPreprint

More on IFNG

Spatial memory

upin mice1upin rats1

2 studies
  1. Insulin improves spatial memory in 5xFAD mice.

    “improved spatial memory in both acquisition and reversal probe trials in the Morris water maze”

    Animalsin 5xFAD mice1.750 Ufemales

    Intranasal insulin treatment ameliorates spatial memory, muscular strength, and frailty deficits in 5xFAD mice

    Physiology & behavior

  2. Insulin improves spatial memory in rats (8 days after the last insulin injection).

    “paralleled increased spatial memory performance in the Morris Water Maze behavioral task”

    Animals8 days after the last insulin injection20 mU5 days

    Insulin activates microglia and increases COX-2/IL-1β expression in young but not in aged hippocampus

    Brain research

Delirium duration

downin humans1no changein humans1HR 0.34–0.7

1 study
  1. Insulin decreases delirium duration in humans (aged ≤88 years).

    “Participants aged ≤88 years demonstrated a significant reduction in delirium duration [insulin: 3.88 (2.87, 6.92) days vs control: 7.03 (4.67, 9.66) days, HR 0.34, CI 0.16–0.74; P = 0.006”

    Human trialaged ≤88 yearsintranasal

    Long-acting intranasal insulin for the treatment of delirium-a randomised clinical trial

    Age and ageing

  2. Insulin showed no clear effect on delirium duration in humans.

    “In the primary ITT analyses, the median (IQR) days of delirium were 4.82 (2.93, 9.21) in the insulin arm and 6.79 (3.97, 9.76) in the control arm [Mann–Whitney U: P =.27, unadjusted hazard ratio (HR) 0.9; CI 0.57–1.43; P =.66, adjusted HR 0.7; CI 0.43–1.15; P =.16].”

    Human trialintranasaln = 97

    Long-acting intranasal insulin for the treatment of delirium-a randomised clinical trial

    Age and ageing

  3. Insulin decreases delirium duration in humans (delirium) (3.9 vs 7.0 days (HR 0.34, 0.16-0.74; P = .006)).

    “participants aged ≤88 years showing shorter delirium duration with intranasal insulin [n = 46; intranasal insulin: median 3.9 (IQR 2.9, 6.9) days vs control: 7.0 (4.7, 9.7); HR 0.34, 0.16-0.74; P = .006]”

    Human trialdeliriumlong-acting insulin20 IU twice dailyn = 46

    Long-acting intranasal insulin for the treatment of delirium-a randomised clinical trial

    Age and ageing

  4. Insulin showed no clear effect on delirium duration in humans (delirium) (4.8 vs 6.8 days (HR 0.7, 95% CI 0.43-1.15; P = .16)).

    “Median delirium duration [days (IQR)] was 4.8 [2.9, 9.2] for intranasal insulin and 6.8 [4.0, 9.8] for the control (HR 0.7, 95% CI 0.43-1.15; P = .16).”

    Human trialdeliriumlong-acting insulin20 IU twice dailyn = 97

    Long-acting intranasal insulin for the treatment of delirium-a randomised clinical trial

    Age and ageing

Length of stay

downin humans1HR 0.56

1 study
  1. Insulin decreases length of stay in humans.

    “Participants in the intranasal insulin group had a shorter acute length of stay, median days (IQR) 7.93 (4.62, 14.48) for insulin and 12.91 (6.86, 16.79) for the control (HR 0.56, CI 0.35–0.89, P =.014).”

    Human trialintranasal

    Long-acting intranasal insulin for the treatment of delirium-a randomised clinical trial

    Age and ageing

  2. Insulin decreases length of stay in humans (delirium) (7.9 vs 12.9 days (HR 0.56, 0.35-0.89; P = .014)).

    “Median acute LOS (days) was 7.9 [4.6, 14.5] for intranasal insulin and 12.9 [6.9, 16.8] for the control (HR 0.56, 0.35-0.89; P = .014).”

    Human trialdeliriumlong-acting insulin20 IU twice dailyn = 97

    Long-acting intranasal insulin for the treatment of delirium-a randomised clinical trial

    Age and ageing

S100β

downin humans1

1 study
  1. Insulin decreases S100β in humans.

    “Besides, the serum levels of IL-6, TNF-α and S100β at T2−5 in the insulin group were significantly lower than those of the control group”

    Human trialintranasalserumstarting 2 days before surgery until 1 h before admission to the operating roomn = 61

    Efficacy and safety of intranasal insulin on postoperative cognitive dysfunction in elderly patients after laparoscopic radical resection of colorectal cancer: a double-blind pilot study

    Frontiers in aging neuroscience

  2. Insulin decreases S100β in humans after laparoscopic radical resection of colorectal cancer (mean difference at T2, -8.30).

    “S100β: mean difference at T2, -8.30, p = 0.019; T3, -23.95, p = 0.020; T4, -20.01, p = 0.023; T5, -17.67, p = 0.010”

    Human trialafter laparoscopic radical resection of colorectal cancerserumn = 61

    Efficacy and safety of intranasal insulin on postoperative cognitive dysfunction in elderly patients after laparoscopic radical resection of colorectal cancer: a double-blind pilot study

    Frontiers in aging neuroscience

More on S100β

TNF-alpha

downin humans1

1 study
  1. Insulin decreases TNF-alpha in humans.

    “Besides, the serum levels of IL-6, TNF-α and S100β at T2−5 in the insulin group were significantly lower than those of the control group”

    Human trialintranasalserumstarting 2 days before surgery until 1 h before admission to the operating roomn = 61

    Efficacy and safety of intranasal insulin on postoperative cognitive dysfunction in elderly patients after laparoscopic radical resection of colorectal cancer: a double-blind pilot study

    Frontiers in aging neuroscience

  2. Insulin decreases TNF-alpha in humans after laparoscopic radical resection of colorectal cancer (mean difference at T2, -3.19).

    “TNF-α: mean difference at T2, -3.19, p = 0.002; T3, -2.35, p = 0.028; T4, -2.30, p = 0.019; T5, -1.96, p = 0.0181”

    Human trialafter laparoscopic radical resection of colorectal cancerserumn = 61

    Efficacy and safety of intranasal insulin on postoperative cognitive dysfunction in elderly patients after laparoscopic radical resection of colorectal cancer: a double-blind pilot study

    Frontiers in aging neuroscience

More on TNF-alpha

Walking speed

upin humans1

1 study
  1. Insulin improves walking speed in humans (~ 6.42 cm/s).

    “INI-treated participants walked faster on-treatment (NW ~ 6.42 cm/s; ITT-Model = 0.002, PP-Model = 0.003; DTW ~ 5.8 cm/s; ITT-Model = 0.006, PP-Model = 0.01).”

    Human trial24 weeks with 24 weeks of follow-upn = 244

    MemAID: Memory advancement with intranasal insulin vs. placebo in type 2 diabetes and control participants: a randomized clinical trial

    Journal of neurology

  2. Insulin improves walking speed in humans (type 2 diabetes mellitus) (~ 7 cm/s).

    “DM-INI had faster NW (~ 7 cm/s; p = 0.025) and DTW on-treatment (p = 0.007; p = 0.812 adjusted for baseline difference) than DM-Placebo.”

    Human trialtype 2 diabetes mellitus40 IU24 week

    MemAID: Memory advancement with intranasal insulin vs. placebo in type 2 diabetes and control participants: a randomized clinical trial

    Journal of neurology

All 163

What is insulin linked with?

89

Studies link insulin with 89 measures, most often mortality (12 studies), postoperative delirium (8) and hypoglycemia (8).

Mortality

upin humans11downin humans1RR 3.37

12 studies
  1. Insulin is associated with mortality in humans (type 2 diabetes; insulin alone) (RR 3.37, 95% CI 3.10 to 3.67).

    “Insulin alone and combined with oral glucose-lowering medications or glucagon-like peptide-1 receptor agonists were associated with increased mortality”

    Humanstype 2 diabetes; insulin alone2018 to 2023

    Early type 2 diabetes diagnosis linked to higher death rates

    BMJ open diabetes research & care

  2. Insulin is associated with mortality in humans (HR 0.75, 95% CI 0.67-0.84).

    “All active therapies were associated with lower mortality compared with no observed therapy, including GLP-1RA/SGLT2i (HR 0.71, 95% CI 0.58-0.87), metformin (HR 0.60, 95% CI 0.55-0.66), and insulin (HR 0.75, 95% CI 0.67-0.84).”

    HumansType 2 diabetes after isolated coronary artery bypass grafting; compared with no observed therapyn = 19,237

    Initial Diabetes Therapy After Coronary Artery Bypass Grafting and Long-Term Outcomes

    Journal of the American Heart Association

  3. Insulin is linked with a higher risk of mortality in T2DM patients after COVID-19.

    “After adjusting for sex, age, following factors were independently associated with increased long-term mortality in T2DM patients after COVID-19: older age, male sex, insulin therapy.”

    Humansin T2DM patients after COVID-19

    Mortality in patients with type 2 diabetes mellitus following coronavirus infection during the acute phase and long-term period

    Diabetes Mellitus

  4. Insulin is linked with a higher risk of mortality in humans (veterans with pulmonary hypertension and diabetes).

    “Conversely, insulin use was associated with higher mortality.”

    Humansveterans with pulmonary hypertension and diabetes

    Association of Antidiabetic Medication Classes With Survival Outcomes in Pulmonary Hypertension Patients With Diabetes

    Pulmonary circulation

  5. Insulin is linked with a higher risk of mortality in humans (incident diabetic foot ulcer).

    “Independent predictors of 1-year mortality included male sex, older age, hospital-acquired DFU, insulin, major amputation, cardiovascular disease, cancer, dementia, ESKD, and liver disease.”

    Humansincident diabetic foot ulcer1 year

    GLP-1 Receptor Agonists Are Associated With Reduced Mortality Following Diabetic Foot Ulcers: A Nationwide Observational Study

    Diabetes care

  6. Insulin is linked with a higher risk of mortality in home care services (HR 1.18 (CI 1.11-1.25)).

    “Women in the "insulin only" group had a higher risk of all-cause mortality (HR 1.18 (CI 1.11-1.25)) than women without diabetes”

    Humansin home care servicesfemales

    All-cause and cause-specific mortality in older people with and without diabetes in Norwegian home care services: a nationwide registry study

    BMC geriatrics

  7. Insulin is associated with mortality in humans (type 2 diabetes).

    “Mortality was higher in the insulin group and lower in the oral antidiabetic drug group.”

    Humanstype 2 diabetes5 yearsn = 616

    Five-Year Follow-Up of Diabetic Complications and Geriatric Alterations in French Older Patients with Type 2 Diabetes According to Treatment Modalities: The Observational Prospective GERODIAB Cohort

    Drugs & aging

  8. Insulin is linked with a higher risk of mortality in humans (HR 1.55, 95% CI 1.51–1.59).

    “It increased moderately with insulin (HR=1.55; 95% CI 1.51 to 1.59)”

    Humanscompared with no use of each study medication, adjusted for concurrent use of other study drugs

    Independent effects of 15 commonly prescribed drugs on all-cause mortality among US elderly patients with type 2 diabetes mellitus

    BMJ open diabetes research & care

  9. Insulin is linked with a higher risk of mortality in humans (HbA1c <52 mmol/mol (<7.0%)) (HR 2.22 (95% CI 1.12-4.43)).

    “the sulphonylurea and insulin treatment groups had higher mortality when HbA1c levels were <52 mmol/mol (<7.0%)”

    HumansHbA1c <52 mmol/mol (<7.0%)

    Glycaemic control and mortality in older people with type 2 diabetes: The Fremantle Diabetes Study Phase II

    Diabetes, obesity & metabolism

  10. Insulin is associated with mortality in humans (pooled across mixed human studies in patients with cancer) (HR=2.03, 95% CI: 1.63-2.51).

    “whereas insulin use was associated with higher ACM (HR=2.03, 95% CI: 1.63-2.51, P<0.0001)”

    Reviewpooled across mixed human studies in patients with cancer

    Heterogeneous associations of antidiabetic medications with cancer prognosis: Evidence from 61 studies with over 1.1 million patients

    Pharmacological research

All 12

Postoperative delirium

downin humans8OR 0.195–0.37

8 studies
  1. Insulin is associated with postoperative delirium in humans (surgical patients with type 2 diabetes mellitus) (adjusted OR = 0.195, 95% CI: 0.036-0.826; incidence 10.7% versus 36.4% with saline).

    “Intranasal insulin was associated with reduced POD risk in T2DM patients (adjusted OR = 0.195, 95% CI: 0.036-0.826, P = 0.035)”

    Human trialsurgical patients with type 2 diabetes mellitusperioperativen = 50

    Effects of intranasal insulin on postoperative delirium in older patients with and without type 2 diabetes mellitus: a secondary analysis of a randomized clinical trial

    Aging clinical and experimental research

  2. Insulin lowers the risk of postoperative delirium in humans (postoperative days 1, 2, and 3 after radical esophagectomy) (16.7% vs. 46.7%, P = 0.012).

    “long-acting insulin pretreatment significantly reduced POD incidence (16.7% vs. 46.7%, P = 0.012)”

    Human trialpostoperative days 1, 2, and 3 after radical esophagectomycentral nervous system30Usingle dose one day preoperativelyn = 60

    Effects of intranasal long-acting insulin pretreatment on postoperative delirium and the NLRP3/caspase-1/IL-1β pathway in older patients with esophageal cancer Running title: intranasal long-acting insulin and postoperative delirium

    Research SquarePreprint

  3. Insulin lowers the risk of postoperative delirium in humans (10.9% vs. 30.4%).

    “Within the initial five postoperative days, POD incidence in Group I was reduced (10.9% vs. 30.4%, P = 0.020).”

    Human trialintranasal5 daysn = 96

    Effect of perioperative intranasal insulin on postoperative delirium in elderly hip fracture patients undergoing general anesthesia: a randomized controlled study

    BMC anesthesiology

  4. Insulin lowers the risk of postoperative delirium in humans (undergoing hip fracture surgery under general anesthesia) (10.9% vs. 30.4%, P = 0.020).

    “Patients treated with INI showed a significantly lower incidence of POD within the 5-day postoperative period (10.9% vs. 30.4%, P = 0.020).”

    Human trialundergoing hip fracture surgery under general anesthesia20 units in 0.5 mL twice dailybeginning two days preoperatively and continuing for five daysn = 92

    Effect of perioperative intranasal insulin on postoperative delirium in elderly hip fracture patients undergoing general anesthesia: a randomized controlled study

    BMC anesthesiology

  5. Insulin lowers the risk of postoperative delirium in humans (scheduled for elective orthopaedic surgery or pancreatic surgery with general anaesthesia) (10.9% vs 26.6%, P = 0.024).

    “decreased the incidence of POD within the 3-day postoperative period in Group I than in Group S (10.9% vs 26.6%, P = 0.024)”

    Human trialscheduled for elective orthopaedic surgery or pancreatic surgery with general anaesthesiaintranasal administration40 IU/400 μLfrom 5 minutes before anaesthesia induction until 3 days postoperativelyn = 140

    Effect of intranasal insulin on perioperative cognitive function in older adults: a randomized, placebo-controlled, double-blind clinical trial

    Age and ageing

  6. Insulin lowers the risk of postoperative delirium in humans (undergoing joint replacement) (8.33% vs 23.23%, P=0.004).

    “8 patients (8.33%) occurred POD in insulin group within 5 days after surgery, significantly fewer than 23 patients (23.23%) in placebo group (P=0.004).”

    Human trialundergoing joint replacementtwice 40 IUn = 212

    Effect of intranasal insulin on osteocalcin levels and postoperative delirium in elderly patients undergoing joint replacement

    medRxivPreprint

  7. Insulin lowers the risk of postoperative delirium in humans (preoperative surgical patients) (OR 0.24; 95% CI 0.17 to 0.34).

    “Intranasal insulin significantly reduced the risk of POD (OR 0.24; 95% CI 0.17 to 0.34; p < 0.001; I2 = 0%).”

    Reviewpreoperative surgical patientsn = 888

    Effect of preoperative intranasal insulin on postoperative delirium in adult surgical patients: a systematic review, meta-analysis, and trial sequential analysis

    Perioperative medicine (London, England)

  8. Insulin lowers the risk of postoperative delirium in surgical patients (risk ratio = 0.36; 95% confidence interval = 0.28-0.46).

    “The overall incidence of delirium was significantly lower in patients treated with intranasal insulin (risk ratio = 0.36; 95% confidence interval = 0.28-0.46; p < 0.001).”

    Reviewin surgical patientsn = 1,039

    Efficacy of intranasal insulin in reducing the incidence of postoperative delirium: A systematic review and meta-analysis of randomised controlled trials

    Journal of perioperative practice

  9. Insulin lowers the risk of postoperative delirium in humans among adults undergoing surgery (OR: 0.37, 95% CI: 0.22, 0.63).

    “intranasal insulin significantly reduced the incidence of postoperative delirium among adults undergoing surgery (OR: 0.37, 95% CI: 0.22, 0.63)”

    Reviewamong adults undergoing surgeryn = 739

    Use of intranasal insulin on postoperative delirium: A systematic review and meta-analysis of randomised controlled trials

    Indian journal of anaesthesia

More on Postoperative delirium

Hypoglycemia

upin humans7upin silico1OR 4.22–4.64

8 studies
  1. Insulin is associated with hypoglycemia in humans (average 0.13% per month).

    “insulin had the highest percentage of individuals affected with hypoglycemia (average 0.13% per month)”

    Humans

    Use of Second-line Diabetes Mellitus Medications and Adverse Events Among Older Adults After the Introduction of Glucagon-like Peptide-1 Receptor Agonists in Ontario, Canada: A Retrospective Cohort Study

    Canadian journal of diabetes

  2. Insulin is linked with a higher risk of hypoglycemia in humans (hospitalized patients with type 2 diabetes) (OR 4.22, 95% CI 2.14-6.28).

    “The use of basal-bolus insulin regimen (odds ratio: 4.22; 95% confidence interval: 2.14-6.28; p<0.001)”

    Humanshospitalized patients with type 2 diabetes

    In-hospital linagliptin for management simplification and hypoglycemia reduction in very old patients with type 2 diabetes

    Medicina clinica

  3. Insulin is linked with a higher risk of hypoglycemia in humans (dementia and T2DM) (OR = 4.64, p < 0.001).

    “insulin had the highest risk (OR = 4.64, p < 0.001)”

    Humansdementia and T2DMtwo-yearn = 3,877

    The Risk Factors of Severe Hypoglycemia in Older Patients with Dementia and Type 2 Diabetes Mellitus

    Journal of personalized medicine

  4. Insulin is linked with a higher risk of hypoglycemia in humans (patients aged over 65 on insulin versus sulfonylureas) (34% vs 5% with more than one documented episode (sulphonylurea); 2% metformin-only; p<0.001).

    “27/79(34%) insulin-treated patients had >1 documented hypoglycaemia episode, compared to 4/85(5%) sulphonylurea-treated patients”

    Humanspatients aged over 65 on insulin versus sulfonylureasn = 79

    Are we missing hypoglycaemia? Elderly patients with insulin-treated diabetes present to primary care frequently with non-specific symptoms associated with hypoglycaemia

    Primary care diabetes

  5. Insulin is linked with a higher risk of hypoglycemia in patients with type 2 diabetes.

    “Event rates and cost of stay were highest in patients treated with sulfonylurea- or insulin-based regimens.”

    Humansin patients with type 2 diabetes

    Direct medical costs of severe hypoglycaemic events in patients with type 2 diabetes in England: A retrospective database study

    International journal of clinical practice

  6. Insulin raises the risk of hypoglycemia in elderly individuals with type 2 diabetes.

    “Insulin should be used with caution because it is associated with higher risk of hypoglycemia”

    Reviewin elderly individuals with type 2 diabetes

    Pharmacological treatment of type 2 diabetes in elderly patients with heart failure: randomized trials and beyond

    Heart failure reviews

  7. Insulin raises the risk of hypoglycemia in humans.

    “The evidence suggests that sulfonylureas and insulin regimens should be used with caution due to a high risk of hypoglycemia.”

    Review

    Type 2 diabetes management in people aged over seventy-five years: targets and treatment strategies

    Maturitas

  8. Insulin raises the risk of hypoglycemia in silico (modeled drug-induced hypoglycemia) (8.64 events per person-year (65-79 years); 12.06 events per person-year (80 years and older)).

    “Incidence rates of drug-induced hypoglycemia were the highest for basal insulin and sulfonylureas”

    In silicomodeled drug-induced hypoglycemiabasal

    Preventing Unnecessary Costs of Drug-Induced Hypoglycemia in Older Adults with Type 2 Diabetes in the United States and Canada

    PloS one

More on Hypoglycemia

Sarcopenia

upin humans3downin humans1

4 studies
  1. Insulin is associated with sarcopenia in humans (Type 2 diabetes mellitus for at least 12 months; multivariable analysis) (aOR 0.081, 95% CI 0.010–0.649).

    “whereas insulin use was inversely associated (aOR 0.081, 95% CI: 0.010–0.649; p = 0.018).”

    HumansType 2 diabetes mellitus for at least 12 months; multivariable analysisn = 100

    Sarcopenia in Middle-Aged Adults With Type 2 Diabetes Mellitus: Prevalence, Associated Factors and Relationship With Gonadal Hormones

    Research SquarePreprint

  2. Insulin is associated with sarcopenia in humans (Outpatients with type 2 diabetes).

    “Risk was higher in the group aged ≥ 65 years and the group treated with insulin for ≥ 5 years (p < 0.05).”

    HumansOutpatients with type 2 diabetes≥ 5 years

    Screening for sarcopenia in outpatients with type 2 diabetes in Hung Yen Province

    Tạp chí Y học Cộng đồng

  3. Insulin is linked with a higher risk of sarcopenia in male patients with T2DM.

    “decreased serum albumin (Alb), elevated alkaline phosphatase, and insulin use were also significant risk factors for sarcopenia in male patients with T2DM.”

    Humansin male patients with T2DMmales

    Muscle mass and function in patients with type 2 diabetes mellitus: a characteristic analysis based on sex, age, and BMI

    Frontiers in endocrinology

  4. Insulin is associated with sarcopenia in humans (unadjusted logistic regression).

    “In logistic regression analysis, medication with insulin was significantly associated with the prevalence of sarcopenia;”

    Humansunadjusted logistic regression

    Poor glycemic control rather than types of diabetes is a risk factor for sarcopenia in diabetes mellitus: The MUSCLES-DM study

    Journal of diabetes investigation

More on Sarcopenia

Dementia

upin humans3downin humans1OR 0.11

4 studies
  1. Insulin is linked with a lower risk of dementia in humans (compared with placebo, Bayesian network meta-analysis) (OR 0.11, 95% CrI 0.1–0.12).

    “Insulin [OR = 0.11, 95% CrI (0.1, 0.12)]”

    Humanscompared with placebo, Bayesian network meta-analysis

    The impact of antidiabetic drugs on dementia risk: a Bayesian network meta-analysis

    Frontiers in endocrinology

  2. Insulin is linked with a higher risk of dementia in humans (HR ≈ 1.26; 95% CI 1.08–1.48).

    “Cause-specific Cox models supported a higher dementia hazard in insulin users (HR ≈ 1.26; 95% CI 1.08–1.48; p = 0.004)”

    Humansafter inverse probability of treatment and censoring weighting; competing death handled by cause-specific models1996–2020n = 6,671

    Insulin use in diabetes association with cognitive impairment and dementia incidence

    BMC pharmacology & toxicology

  3. Insulin is linked with a higher risk of dementia in humans (HR: 1.34, 95% CI 1.01 to 1.78).

    “insulin (HR: 1.34, 95% CI 1.01 to 1.78; p=0.046)”

    Humans

    Associations of coprescribed medications for chronic comorbid conditions in very old adults with clinical dementia: a retrospective cohort study using insurance claims data

    BMJ open

  4. Insulin raises the risk of dementia in humans (compared with other antidiabetic agents).

    “whereas insulin is associated with an elevated risk of dementia”

    Reviewcompared with other antidiabetic agents

    Antidiabetic agents and dementia risk in type 2 diabetes: A systematic review and network meta-analysis

    Diabetes, obesity & metabolism

More on Dementia

Postoperative cognitive dysfunction

downin humans3

3 studies
  1. Insulin lowers the risk of postoperative cognitive dysfunction in humans (4 (13.3%) vs. 12 (38.7%)).

    “The insulin group had a significantly lower POCD rate compared with the control group at postoperative day 7 [4 (13.3%) vs. 12 (38.7%), p = 0.024].”

    Human trialintranasalstarting 2 days before surgery until 1 h before admission to the operating roomn = 61

    Efficacy and safety of intranasal insulin on postoperative cognitive dysfunction in elderly patients after laparoscopic radical resection of colorectal cancer: a double-blind pilot study

    Frontiers in aging neuroscience

  2. Insulin lowers the risk of postoperative cognitive dysfunction in humans after laparoscopic radical resection of colorectal cancer (4(13.3%) vs. 12 (38.7%)).

    “The insulin group had a significantly lower POCD rate compared with the control group at postoperative day 7 [4(13.3%) vs. 12 (38.7%), p = 0.024].”

    Human trialafter laparoscopic radical resection of colorectal cancerpostoperative 7 daysn = 61

    Efficacy and safety of intranasal insulin on postoperative cognitive dysfunction in elderly patients after laparoscopic radical resection of colorectal cancer: a double-blind pilot study

    Frontiers in aging neuroscience

  3. Insulin lowers the risk of postoperative cognitive dysfunction in humans (metabolic syndrome undergoing noncardiac surgery) (20.8% vs 45.1% (P = 0.008)).

    “POCD occurred in the insulin group on the 7th postoperative day in 11 (20.8%) patients, which was fewer than the 23 (45.1%) patients in the placebo group (P = 0.008).”

    Human trialmetabolic syndrome undergoing noncardiac surgery40 IU7 daysn = 116

    Protective effect of intranasal insulin on postoperative cognitive dysfunction in elderly patients with metabolic syndrome undergoing noncardiac surgery: a randomized clinical trial

    Aging clinical and experimental research

  4. Insulin lowers the risk of postoperative cognitive dysfunction in humans (postoperative).

    “reduced incidence of postoperative cognitive dysfunction are demonstrated”

    Reviewpostoperative

    Intranasal insulin in the correction of cognitive impairments with central insulin resistance. A review

    Consilium Medicum

More on Postoperative cognitive dysfunction

Type 2 diabetes

upin humans3

3 studies
  1. Insulin predicts type 2 diabetes in humans among women with GDM (aHR 3.81).

    “Insulin therapy during pregnancy predicted progression among women with GDM (adjusted hazard ratio 3.81).”

    Humansamong women with GDM

    Gestational diabetes mellitus across the lifespan: Pregnancy and beyond

    Journal of Association of Clinical Endocrinologist and Diabetologist of Bangladesh

  2. Insulin is associated with type 2 diabetes in humans during pregnancy in GDM patients (80% vs 43%).

    “insulin use (80% vs 43%)”

    Humansduring pregnancy in GDM patientsfemales

    Risk Factors for Progression to Type 2 Diabetes Postgestational Diabetes —A Retrospective Cohort Study

    ADA Scientific Sessions 2025 abstract

  3. Insulin predicts type 2 diabetes in humans (regardless of metabolic parameters and insulin resistance).

    “Hyperinsulinemia predicted the development of T2D, regardless of metabolic parameters and insulin resistance.”

    Humansregardless of metabolic parameters and insulin resistance10 years

    Hyperinsulinemia counteracts inflammation by suppressing IFNγ and inducing senescence in CD4 + T cells of patients with rheumatoid arthritis

    medRxivPreprint

More on Type 2 diabetes

Frailty

upin humans3

3 studies
  1. Insulin is associated with frailty in older adults with type 2 diabetes.

    “Frailty levels were significantly higher among women, those with lower education, longer disease duration, insulin or OAD+insulin users, and individuals with complications.”

    Humansin older adults with type 2 diabetesn = 384

    Frailty in older adults with type 2 diabetes: the importance of metabolic control and treatment adherence

    BMC geriatrics

  2. Insulin is associated with frailty in humans.

    “Some formulations, such as glinide, sodium-glucose cotransporter 2 inhibitors, and insulin, are associated with an increased frequency of frailty”

    Humans

    Relationship Between Frailty and Diabetic Pharmacologic Therapy in Older Adults with Type 2 Diabetes: A Cross-Sectional Study

    Drugs & aging

  3. Frailty is associated with insulin in internal medicine inpatients with diabetes mellitus or hyperglycemia.

    “Baseline treatments showed a significant predominance of insulin use in the frailest groups.”

    Humansin internal medicine inpatients with diabetes mellitus or hyperglycemia

    Glycemic control and prescription profiles in internal medicine inpatients: The role of frailty

    European journal of internal medicine

Bone fracture

upin humans3HR 1.1–1.34

3 studies
  1. Insulin predicts bone fracture in humans (type 2 diabetes and overweight or obesity) (HR 1.34, 95% CI, 1.08-1.66).

    “insulin use (HR 1.34, 95% CI, 1.08-1.66) were significant diabetes-related predictors of all clinical fractures.”

    Human trialtype 2 diabetes and overweight or obesity

    Predictors of Fracture in Middle-Aged and Older Adults With Type 2 Diabetes and Overweight or Obesity

    The Journal of clinical endocrinology and metabolism

  2. Insulin is linked with a higher risk of bone fracture in humans (adjusted for fracture risk factors and diabetes-related comorbidities) (HR 1.10 (95% CI 1.07-1.12)).

    “Use of insulin was independently associated with greater risk of fracture (HR = 1.10, 95% CI 1.07-1.12).”

    Humansadjusted for fracture risk factors and diabetes-related comorbiditiesmalesn = 652,901

    Glycemic Control and Insulin Treatment Alter Fracture Risk in Older Men With Type 2 Diabetes Mellitus

    Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research

  3. Insulin is associated with bone fracture in humans (type 2 diabetes).

    “Several diabetes-related factors are associated with increased fracture risk, including exogenous insulin therapy, vascular complications, and poor glycaemic control”

    Reviewtype 2 diabetesbone

    Contributors to impaired bone health in type 2 diabetes

    Trends in endocrinology and metabolism: TEM

More on Bone fracture

Hip fracture

upin humans3HR 2.17

3 studies
  1. Insulin is linked with a higher risk of hip fracture in humans (initiating antidiabetic drugs) (HR 2.17, 95% CI 1.77-2.66).

    “Patients prescribed insulin for hip and vertebral fractures' adjusted HRs were 2.17 (95% CI 1.77-2.66) and 1.45 (95% CI 1.24-1.70), respectively.”

    Humansinitiating antidiabetic drugs

    Hip and vertebral fracture risk after initiating antidiabetic drugs in Japanese elderly: a nationwide study

    Journal of bone and mineral metabolism

  2. Insulin is linked with a higher risk of hip fracture in patients with type 2 diabetes.

    “Thiazolidinediones and insulin use are factors with the greater magnitude of strength of association among those significantly associated with hip fracture.”

    Humansin patients with type 2 diabetes

    Lifetime risks of hip fracture in patients with type 2 diabetic: Taiwan Diabetes Study

    Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA

  3. Insulin is associated with hip fracture in humans (Patients with type 2 diabetes).

    “In patients with diabetes, significant csHRs for incident hip fracture were male sex (protective), body mass index (protective), insulin use, and renal impairment.”

    HumansPatients with type 2 diabetesMean 14.1 yearsn = 1,291

    Influence of Premature Mortality on the Link Between Type 2 Diabetes and Hip Fracture: The Fremantle Diabetes Study

    The Journal of clinical endocrinology and metabolism

More on Hip fracture

Mini-Mental State Examination score

upin humans1

1 study
  1. Insulin is associated with mini-Mental State Examination score in humans (surgical patients with type 2 diabetes mellitus) (MMSE: β = 1.042, 95% CI: 0.230-1.854; MoCA-B: β = 1.093, 95% CI: 0.013-2.173).

    “insulin positively correlated with perioperative changes of MMSE and MoCA-B scores in both T2DM”

    Human trialsurgical patients with type 2 diabetes mellitusperioperativen = 50

    Effects of intranasal insulin on postoperative delirium in older patients with and without type 2 diabetes mellitus: a secondary analysis of a randomized clinical trial

    Aging clinical and experimental research

FFA-palmitate Ra suppression by niacin

downin humans1

1 study
  1. Insulin is associated with FFA-palmitate Ra suppression by niacin in upper-body obesity and/or type 2 diabetes mellitus (r = -0.93, P < 0.001).

    “The suppression of FFA-palmitate Ra by insulin on the saline control day and by niacin after an overnight infusion were highly correlated (r = -0.93, P < 0.001).”

    Human trialin upper-body obesity and/or type 2 diabetes mellitusadipose tissuen = 10

    Adipose Tissue Resistance to the Antilipolytic Effect of Insulin and Niacin in Humans With Obesity

    Diabetes

More on FFA-palmitate Ra suppression by niacin

All 89

What acts on insulin?

5

Studies name 5 things that act on insulin, among them liraglutide, multidomain lifestyle program and henagliflozin.

Liraglutide

downin humans1

1 study
  1. Liraglutide decreases insulin in humans (added to insulin therapy).

    “despite the daily doses and number of insulin injections per day being reduced”

    Human trialadded to insulin therapy6 monthsn = 20

    Efficacy and safety of liraglutide added to insulin therapy in elderly patients with type 2 diabetes

    Endocrinology, diabetes & metabolism

  2. Liraglutide decreases insulin in humans (added to insulin therapy) (17.0 (11.8‐23.3) to 9.0 (6.8‐11.3) units/d, P = 0.0009).

    “Six months after Lira was added, the TDD significantly decreased from 17.0 (11.8‐23.3) [median (IQR)] to 9.0 (6.8‐11.3) units/d (P = 0.0009).”

    Human trialadded to insulin therapySix monthsn = 20

    Efficacy and safety of liraglutide added to insulin therapy in elderly patients with type 2 diabetes

    Endocrinology, diabetes & metabolism

More on Liraglutide

Multidomain lifestyle program

downin humans1

1 study
  1. Multidomain lifestyle program decreases insulin in humans (long-standing type 2 diabetes) (discontinued within the first month).

    “Insulin was successfully tapered and discontinued within the first month of enrolment.”

    Human triallong-standing type 2 diabetesfirst monthmalesn = 1

    Sustained Insulin Independence Following Lifestyle Intervention in a 78-Year-Old Patient With Long-Standing Type 2 Diabetes: A Six-Year Follow-Up Case Report

    Cureus

More on Multidomain lifestyle program

Henagliflozin

downin humans1

1 study
  1. Henagliflozin decreases insulin in severely hyperglycaemic T2DM patients.

    “The TAR, insulin dosage, mean glucose (MG) and glucose management indicator (GMI) in the henagliflozin+CSII group were significantly lower than those in the CSII group.”

    Human trialin severely hyperglycaemic T2DM patients7-dayn = 210

    A Multicentre, Randomised, Controlled, Open-Label Study of Continuous Subcutaneous Insulin Infusion Plus Henagliflozin for Treating Type 2 Diabetes Mellitus Patients With Severe Hyperglycaemia

    Diabetes, obesity & metabolism

More on Henagliflozin

Roux-en-y gastric bypass

downin humans1

1 study
  1. Roux-en-y gastric bypass is linked with lower insulin in humans (morbidly obese elderly patients) (34.0% vs 15.2%, p = 0.03).

    “significant decrease in insulin use (16/47, 34.0% pre-operatively vs 7/47, 15.2% post-operatively; p = 0.03)”

    Humansmorbidly obese elderly patientsmedian 39 monthsn = 47

    Increased Metabolic Benefit for Obese, Elderly Patients Undergoing Roux-en-Y Gastric Bypass vs Sleeve Gastrectomy

    Obesity surgery

More on Roux-en-y gastric bypass

Menopause

downin humans1

1 study
  1. Menopause is linked with lower insulin in humans (postmenopause vs premenopause).

    “insulin dosing was lower postmenopause than premenopause”

    Humanspostmenopause vs premenopausefemales

    Cardiovascular (CVD) Risk Factors during the Menopausal Transition among Women with Type 1 Diabetes (T1D)

    ADA Scientific Sessions 2026 abstract

Has insulin been tested in people?

8 of 200 about aging

Yes: 63 trials and 232 observational studies in people have been published, and 179 trials are registered.

Latest change Corneal disease: Phase 2/3 → Phase 3Nov 12, 2026

Every condition in trials

40 of 91

Stopped

  • NCT00237471TerminatedHyperglycemia

    difficulty recruiting patients

  • NCT01137773TerminatedBrain injury

    Slow enrollment

  • NCT00138671TerminatedChronic obstructive pulmonary disease

    See termination reason in detailed description.

  • NCT06601101TerminatedCorneal disease

    Enrollment closed before the planned 36 eyes were reached because of the limited number of eligible patients and the long recruitment period (July 2024 to December 2025); 20 eyes of 19 participants were enrolled.

  • NCT03665350TerminatedHeart failure

    Insulin-HF study was prematurely ended due principally to low recruitment rate.

  • NCT00678145TerminatedPure autonomic failure

    Protocol was terminated due to enrollment + feasibility issues. Aim 2 not conducted. Aims 1 + 3 were conducted in part. During Aim 3 the IRB requested that the study be transitioned under a new protocol (2018-9208) in order to simplify reporting.

Who is developing insulin?

3 companies: Pfizer, Tanabe Pharma and Astellas Pharma.

Companies

Trial sponsors

Funding

182 grants since 2016

National Institute of Diabetes and Digestive and Kidney Diseases$54.4MNational Institute on Aging$43.2MNational Heart, Lung, and Blood Institute$18.2M

How this record changed

  1. Summary rewritten as its findings changed.

    As it read before

    Independent labs report that insulin increases senescence in human cells but decreases it in mice; human trials report less postoperative delirium with intranasal administration but impaired verbal episodic memory during insulin stimulation. Three registered trials concern aging; across uses, 80 ended over a year ago without posted results or citing papers. Authors declare company ties, and developers sponsor some trials.

  2. Summary rewritten as its findings changed.

    As it read before

    Intranasal insulin lowers postoperative delirium risk in human trials; independent labs report improved spatial memory in rats and increased hypoglycemia in humans, but an aged-rat study shows no clear memory effect. Three registered trials concern aging; across uses, 80 trials ended over a year ago without posted results or citing papers. Authors declare developer ties; developers sponsor 32 of 213 trials across uses.

  3. Summary rewritten as its findings changed.

    As it read before

    Human trials report less postoperative delirium with intranasal insulin; independent labs reproduce increased hypoglycemia risk in humans and spatial-memory improvements in rats, alongside a rat study reporting no spatial-memory effect. Three registered trials concern aging; 80 across uses ended over a year ago without posted results or citing papers. Developers sponsor 32 trials, and human papers declare developer ties.

  4. Summary rewritten as its findings changed.

    As it read before

    Human research links insulin to mortality in cancer with predominantly concomitant type 2 diabetes, and vascular dementia in type 2 diabetes versus metformin alone; dapagliflozin and semaglutide reduce insulin. Work spans four independent labs in four countries; 80 trials ended over a year ago without posted results or citing papers, and developers sponsor 31 of 211 registered trials.

  5. Summary written from the findings.

Latest

Dec 2025: 14Jan 2026: 33Feb 2026: 33Mar 2026: 33Apr 2026: 7May 2026: 13Jun 2026: 16Jul 2026: 11Aug 2026: 12Sep 2026: 13Oct 2026: 38Nov 2026: 23246 papers in 12 months
The Journal of Physiology

Exercise and insulin boosted galactose uptake in older men

A randomized crossover trial in eight healthy men averaging 68 years old found that muscles could directly take up galactose, a sugar.A randomized crossover trial in eight healthy men averaging 68 years old found that muscles could directly take up galactose, a sugar.

Randomized trial · 8 peopleInsulin
Molecular Metabolism

Lab-grown human muscle models mimic key exercise responses

Muscle models grown from human donor cells showed gene activity responses to electrical stimulation that overlapped with responses in those donors’ muscles after…Muscle models grown from human donor cells showed gene activity responses to electrical stimulation that overlapped with responses in those donors’ muscles after exercise.

Human cell studyExercise

See all 627 papers on insulin